Literature DB >> 31672086

Toward a New Multi-Dimensional Classification of Traumatic Brain Injury: A Collaborative European NeuroTrauma Effectiveness Research for Traumatic Brain Injury Study.

Benjamin Y Gravesteijn1, Charlie A Sewalt1, Ari Ercole2, Cecilia Akerlund3, David Nelson3, Andrew I R Maas4, David Menon2, Hester F Lingsma1, Ewout W Steyerberg1,5.   

Abstract

Traumatic brain injury (TBI) is currently classified as mild, moderate, or severe TBI by trichotomizing the Glasgow Coma Scale (GCS). We aimed to explore directions for a more refined multidimensional classification system. For that purpose, we performed a hypothesis-free cluster analysis in the Collaborative European NeuroTrauma Effectiveness Research for TBI (CENTER-TBI) database: a European all-severity TBI cohort (n = 4509). The first building block consisted of key imaging characteristics, summarized using principal component analysis from 12 imaging characteristics. The other building blocks were demographics, clinical severity, secondary insults, and cause of injury. With these building blocks, the patients were clustered into four groups. We applied bootstrap resampling with replacement to study the stability of cluster allocation. The characteristics that predominantly defined the clusters were injury cause, major extracranial injury, and GCS. The clusters consisted of 1451, 1534, 1006, and 518 patients, respectively. The clustering method was quite stable: the proportion of patients staying in one cluster after resampling and reclustering was 97.4% (95% confidence interval [CI]: 85.6-99.9%). These clusters characterized groups of patients with different functional outcomes: from mild to severe, 12%, 19%, 36%, and 58% of patients had unfavorable 6 month outcome. Compared with the mild and the upper intermediate cluster, the lower intermediate and the severe cluster received more key interventions. To conclude, four types of TBI patients may be defined by injury mechanism, presence of major extracranial injury and GCS. Describing patients according to these three characteristics could potentially capture differences in etiology and care pathways better than with GCS only.

Entities:  

Keywords:  GCS; classification; clustering; prospective

Year:  2019        PMID: 31672086     DOI: 10.1089/neu.2019.6764

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  9 in total

1.  The Nanotheranostic Researcher's Guide for Use of Animal Models of Traumatic Brain Injury.

Authors:  Brandon Z McDonald; Connor C Gee; Forrest M Kievit
Journal:  J Nanotheranostics       Date:  2021-12-06

Review 2.  Assessing the Severity of Traumatic Brain Injury-Time for a Change?

Authors:  Olli Tenovuo; Ramon Diaz-Arrastia; Lee E Goldstein; David J Sharp; Joukje van der Naalt; Nathan D Zasler
Journal:  J Clin Med       Date:  2021-01-04       Impact factor: 4.241

3.  Decoding health status transitions of over 200 000 patients with traumatic brain injury from preceding injury to the injury event.

Authors:  Tatyana Mollayeva; Andrew Tran; Vincy Chan; Angela Colantonio; Mitchell Sutton; Michael D Escobar
Journal:  Sci Rep       Date:  2022-04-04       Impact factor: 4.379

Review 4.  Epidemiology of Chronic Effects of Traumatic Brain Injury.

Authors:  Juliet Haarbauer-Krupa; Mary Jo Pugh; Eric M Prager; Nicole Harmon; Jessica Wolfe; Kristine Yaffe
Journal:  J Neurotrauma       Date:  2021-08-17       Impact factor: 4.869

5.  Clustering identifies endotypes of traumatic brain injury in an intensive care cohort: a CENTER-TBI study.

Authors:  Cecilia A I Åkerlund; Anders Holst; Nino Stocchetti; Ewout W Steyerberg; David K Menon; Ari Ercole; David W Nelson
Journal:  Crit Care       Date:  2022-07-27       Impact factor: 19.334

6.  Early thrombocytopenia is associated with an increased risk of mortality in patients with traumatic brain injury treated in the intensive care unit: a Finnish Intensive Care Consortium study.

Authors:  Kadri Lillemäe; Teemu Luostarinen; Matti Reinikainen; Stepani Bendel; Ruut Laitio; Sanna Hoppu; Tero Ala-Kokko; Tomi Niemi; Markus B Skrifvars; Rahul Raj
Journal:  Acta Neurochir (Wien)       Date:  2022-07-15       Impact factor: 2.816

7.  Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI.

Authors:  Pashtun Shahim; Adam Politis; Andre van der Merwe; Brian Moore; Vindhya Ekanayake; Sara M Lippa; Yi-Yu Chou; Dzung L Pham; John A Butman; Ramon Diaz-Arrastia; Henrik Zetterberg; Kaj Blennow; Jessica M Gill; David L Brody; Leighton Chan
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

Review 8.  Phenotyping the Spectrum of Traumatic Brain Injury: A Review and Pathway to Standardization.

Authors:  Mary Jo Pugh; Eamonn Kennedy; Eric M Prager; Jeffrey Humpherys; Kristen Dams-O'Connor; Dallas Hack; Mary Katherine McCafferty; Jessica Wolfe; Kristine Yaffe; Michael McCrea; Adam R Ferguson; Lee Lancashire; Jamshid Ghajar; Angela Lumba-Brown
Journal:  J Neurotrauma       Date:  2021-06-10       Impact factor: 5.269

9.  Proceedings of the First Curing Coma Campaign NIH Symposium: Challenging the Future of Research for Coma and Disorders of Consciousness.

Authors:  Jan Claassen; Yama Akbari; Sheila Alexander; Mary Kay Bader; Kathleen Bell; Thomas P Bleck; Melanie Boly; Jeremy Brown; Sherry H-Y Chou; Michael N Diringer; Brian L Edlow; Brandon Foreman; Joseph T Giacino; Olivia Gosseries; Theresa Green; David M Greer; Daniel F Hanley; Jed A Hartings; Raimund Helbok; J Claude Hemphill; H E Hinson; Karen Hirsch; Theresa Human; Michael L James; Nerissa Ko; Daniel Kondziella; Sarah Livesay; Lori K Madden; Shraddha Mainali; Stephan A Mayer; Victoria McCredie; Molly M McNett; Geert Meyfroidt; Martin M Monti; Susanne Muehlschlegel; Santosh Murthy; Paul Nyquist; DaiWai M Olson; J Javier Provencio; Eric Rosenthal; Gisele Sampaio Silva; Simone Sarasso; Nicholas D Schiff; Tarek Sharshar; Lori Shutter; Robert D Stevens; Paul Vespa; Walter Videtta; Amy Wagner; Wendy Ziai; John Whyte; Elizabeth Zink; Jose I Suarez
Journal:  Neurocrit Care       Date:  2021-07-08       Impact factor: 3.210

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.